Diadema Partners’s Soleno Therapeutics SLNO Stock Holding History

Diadema Partners’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$6.76M	–	191
2025 Q3	$6.76M	Buy	+100,000	New	+$7.41M	1.73%	17
2025 Q2	–	Sell	-217,000	Closed	-$15.5M	–	131
2025 Q1	$15.5M	Buy	217,000 +41,600	+24%	+$2.03M	4.05%	9
2024 Q4	$7.88M	Buy	+175,400	New	+$9.09M	3.38%	6

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Diadema Partners's SLNO Position: Q1 2026 in Review

Diadema Partners sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 26,892 shares — an estimated $1.25M sold.

Diadema Partners first reported a position in SLNO in Q4 2024 and held it in 5 quarters. The position peaked at $23.8M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Diadema Partners reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 26,892 Soleno Therapeutics shares in Q1 2026, an estimated $1.25M.
Diadema Partners first reported a position in Soleno Therapeutics in Q4 2024 and held it in 5 quarters.
Diadema Partners's Soleno Therapeutics position peaked at $23.8M in Q2 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.